摘要
X-遗传的细胞凋亡抑制蛋白(XIAP)是细胞凋亡抑制蛋白(IAP)家族的一员,参与肿瘤细胞凋亡的抑制。此特性使其成为治疗癌症的靶点。本研究利用化学描述符号如指纹,主成分,对接能量参数和基于相似性的抗XIAP法,建立定量构效关系(QSAR)模型,我们已获取了相关系数(R) 值为0.803,R2值为0.645,采用SMOreg算法进行10倍交叉验证。我们已评估了这些独立的数据集中的模型,以确定其稳健性和实现相关系数(R) 值为0.793,R2值为0.628。进一步,我们用这些模型对FDA批准的药物和分子药物进行筛选,如锌数据库筛选和基于预测pIC50值对其进行优化。在对接研究中,XIAP-BIR3域的高点击率表明,碘克沙醇(DB01249)和ZINC68678304比著名的四肽抑制剂,AVPI具有更高的结合亲和力。本文综合这些模型在Web服务器中命名为“XIAPin”。望在Web服务器将有利于设计抗XIAP的好的拮抗剂。
关键词: 化学描述符,肽,定量构效关系,虚拟筛选和主成分,X染色体遗传的细胞凋亡抑制蛋白。
图形摘要
Current Cancer Drug Targets
Title:In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP
Volume: 15 Issue: 9
Author(s): Rahul Kumar, Jagat Singh Chauhan and Gajendra Pal Singh Raghava
Affiliation:
关键词: 化学描述符,肽,定量构效关系,虚拟筛选和主成分,X染色体遗传的细胞凋亡抑制蛋白。
摘要: X-linked inhibitor of apoptosis (XIAP) is a member of inhibitor of apoptosis (IAP) family and involved in the suppression of apoptosis in cancer cells. This property makes it a therapeutic target for the cancer therapy. In the present study, we have developed QSAR models using chemical descriptors, fingerprints, principal components, docking energy parameters and similarity-based approach against XIAP. We have achieved correlation (R) of 0.803 with R2 value of 0.645 at 10-fold cross validation using SMOreg algorithm. We have evaluated these models on independent dataset to ascertain its robustness and achieved correlation (R) of 0.793 with R2 value of 0.628. Further, we have used these models for the screening of FDA approved drugs and drug-like molecules from ZINC database and prioritized them on the basis of their predicted pIC50 values. Docking studies of top hits with XIAP-BIR3 domain shows that Iodixanol (DB01249) and ZINC68678304 have higher binding affinities than well-known tetrapeptide inhibitor, AVPI. We have integrated these models in a web server named as “XIAPin”. We hope that this web server will contribute in the designing of nifty antagonists against XIAP.
Export Options
About this article
Cite this article as:
Rahul Kumar, Jagat Singh Chauhan and Gajendra Pal Singh Raghava , In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP , Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/1568009615666150706103537
DOI https://dx.doi.org/10.2174/1568009615666150706103537 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells in Tumour Microenvironment Aid in Prolonged Survival Rate of Cancer Cells and Developed Drug Resistance: Major Challenge in Osteosarcoma Treatment
Current Drug Metabolism Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Nanoparticles based on oleate alginate ester as curcumin delivery system
Current Drug Delivery The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Anticancer Activity and Anti-inflammatory Studies of 5-Aryl-1,4-benzodiazepine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Fused Azolo-Quinoxalines: Candidates for Medicinal Chemistry. A Review of their Biological Applications
Current Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Current Cancer Drug Targets The Urokinase Receptor and its Structural Homologue C4.4A in Human Cancer: Expression, Prognosis and Pharmacological Inhibition
Current Medicinal Chemistry Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma
Current Cancer Drug Targets 3-Hydroxy-2-phenyl-4(1H)-quinolinones as Promising Biologically Active Compounds
Mini-Reviews in Medicinal Chemistry Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets